Integrative Biology Journals

Natural Products and Bioprospecting ›› 2023, Vol. 13 ›› Issue (6): 49-49.DOI: 10.1007/s13659-023-00405-z

• ORIGINAL ARTICLES • Previous Articles     Next Articles

Ginsenoside compound-K attenuates OVX-induced osteoporosis via the suppression of RANKL-induced osteoclastogenesis and oxidative stress

Lingli Ding1, Zhao Gao2, Siluo Wu1, Chen Chen3, Yamei Liu3, Min Wang1, Yage Zhang1, Ling Li1, Hong Zou4, Guoping Zhao5,6,7,8,9,10, Shengnan Qin11, Liangliang Xu1   

  1. 1. Key Laboratory of Orthopaedics and Traumatology, Lingnan Medical Research Center, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, China;
    2. Er Sha Sports Training Center of Guangdong Province, Guangzhou, China;
    3. School of Basic Medical Science, Guangzhou University of Chinese Medicine, Guangzhou, China;
    4. Engineering Laboratory for Nutrition, Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences, Shanghai, China;
    5. Master Lab for Innovative Application of Nature Products, National Center of Technology Innovation for Synthetic Biology, Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences, Tianjin, China;
    6. CAS Key Laboratory of Quantitative Engineering Biology, Shenzhen Institute of Synthetic Biology, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China;
    7. CAS-Key Laboratory of Synthetic Biology, CAS Center for Excellence in Molecular Plant Sciences, Shanghai Institute of Plant Physiology and Ecology, Chinese Academy of Sciences, Shanghai, China;
    8. Bio-Med Big Data Center, Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences, Shanghai, China;
    9. State Key Laboratory of Genetic Engineering, Department of Microbiology and Immunology, School of Life Sciences, Fudan University, Shanghai, China;
    10. Department of Microbiology, The Chinese University of Hong Kong, Hong Kong, China;
    11. Department of Orthopaedics, Guangzhou Institute of Traumatic Surgery, Guangzhou Red Cross Hospital, Medical College, Jinan University, Guangzhou, China
  • Received:2023-07-11 Online:2023-12-26 Published:2023-12-24
  • Contact: Guoping Zhao,E-mail:gpzhao@sibs.ac.cn;Shengnan Qin,E-mail:qinqinsn@163.com;Liangliang Xu,E-mail:xull-2016@gzucm.edu.cn
  • Supported by:
    This work is supported by the grant from National Natural Science Foundation of China (81871778), Guangdong Provincial Science and Technology Collaborative Innovation Center for Sport Science (2019B110210004), and the key project of Sport Research Foundation of Guangdong Province (GDSS2022M005).

Ginsenoside compound-K attenuates OVX-induced osteoporosis via the suppression of RANKL-induced osteoclastogenesis and oxidative stress

Lingli Ding1, Zhao Gao2, Siluo Wu1, Chen Chen3, Yamei Liu3, Min Wang1, Yage Zhang1, Ling Li1, Hong Zou4, Guoping Zhao5,6,7,8,9,10, Shengnan Qin11, Liangliang Xu1   

  1. 1. Key Laboratory of Orthopaedics and Traumatology, Lingnan Medical Research Center, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, China;
    2. Er Sha Sports Training Center of Guangdong Province, Guangzhou, China;
    3. School of Basic Medical Science, Guangzhou University of Chinese Medicine, Guangzhou, China;
    4. Engineering Laboratory for Nutrition, Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences, Shanghai, China;
    5. Master Lab for Innovative Application of Nature Products, National Center of Technology Innovation for Synthetic Biology, Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences, Tianjin, China;
    6. CAS Key Laboratory of Quantitative Engineering Biology, Shenzhen Institute of Synthetic Biology, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China;
    7. CAS-Key Laboratory of Synthetic Biology, CAS Center for Excellence in Molecular Plant Sciences, Shanghai Institute of Plant Physiology and Ecology, Chinese Academy of Sciences, Shanghai, China;
    8. Bio-Med Big Data Center, Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences, Shanghai, China;
    9. State Key Laboratory of Genetic Engineering, Department of Microbiology and Immunology, School of Life Sciences, Fudan University, Shanghai, China;
    10. Department of Microbiology, The Chinese University of Hong Kong, Hong Kong, China;
    11. Department of Orthopaedics, Guangzhou Institute of Traumatic Surgery, Guangzhou Red Cross Hospital, Medical College, Jinan University, Guangzhou, China
  • 通讯作者: Guoping Zhao,E-mail:gpzhao@sibs.ac.cn;Shengnan Qin,E-mail:qinqinsn@163.com;Liangliang Xu,E-mail:xull-2016@gzucm.edu.cn
  • 基金资助:
    This work is supported by the grant from National Natural Science Foundation of China (81871778), Guangdong Provincial Science and Technology Collaborative Innovation Center for Sport Science (2019B110210004), and the key project of Sport Research Foundation of Guangdong Province (GDSS2022M005).

Abstract: Osteoporosis (OP), a systemic and chronic bone disease, is distinguished by low bone mass and destruction of bone microarchitecture. Ginsenoside Compound-K (CK), one of the metabolites of ginsenoside Rb1, has anti-aging, anti-inflammatory, anti-cancer, and hypolipidemic activities. We have demonstrated CK could promote osteogenesis and fracture healing in our previous study. However, the contribution of CK to osteoporosis has not been examined. In the present study, we investigated the effect of CK on osteoclastogenesis and ovariectomy (OVX)-induced osteoporosis. The results showed that CK inhibited receptor activator for nuclear factor-κB ligand (RANKL)-mediated osteoclast differentiation and reactive oxygen species (ROS) activity by inhibiting the phosphorylation of NF-κB p65 and oxidative stress in RAW264.7 cells. In addition, we also demonstrated that CK could inhibit bone resorption using bone marrow-derived macrophages. Furthermore, we demonstrated that CK attenuated bone loss by suppressing the activity of osteoclast and alleviating oxidative stress in vivo. Taken together, these results showed CK could inhibit osteoclastogenesis and prevent OVX-induced bone loss by inhibiting NF-κB signaling pathway.

Key words: Ginsenoside CK, NF-κB signaling pathway, Osteoporosis, Oxidative stress

摘要: Osteoporosis (OP), a systemic and chronic bone disease, is distinguished by low bone mass and destruction of bone microarchitecture. Ginsenoside Compound-K (CK), one of the metabolites of ginsenoside Rb1, has anti-aging, anti-inflammatory, anti-cancer, and hypolipidemic activities. We have demonstrated CK could promote osteogenesis and fracture healing in our previous study. However, the contribution of CK to osteoporosis has not been examined. In the present study, we investigated the effect of CK on osteoclastogenesis and ovariectomy (OVX)-induced osteoporosis. The results showed that CK inhibited receptor activator for nuclear factor-κB ligand (RANKL)-mediated osteoclast differentiation and reactive oxygen species (ROS) activity by inhibiting the phosphorylation of NF-κB p65 and oxidative stress in RAW264.7 cells. In addition, we also demonstrated that CK could inhibit bone resorption using bone marrow-derived macrophages. Furthermore, we demonstrated that CK attenuated bone loss by suppressing the activity of osteoclast and alleviating oxidative stress in vivo. Taken together, these results showed CK could inhibit osteoclastogenesis and prevent OVX-induced bone loss by inhibiting NF-κB signaling pathway.

关键词: Ginsenoside CK, NF-κB signaling pathway, Osteoporosis, Oxidative stress